Skip to main content

Research

New research
Research history

Explore

Search
Cases
Professionals

Resources

Blog
Pricing
Docs

Sign in Create account

Cases

CourtFilingsPetition dateMore filters

Case

Funded debt

Stage

Exit

Next hearing

Last activity

Petition date

Court

Aegerion Pharmaceuticals, Inc. Bankruptcy Case

Aegerion Pharmaceuticals, Inc.

Case No. 19-11632·New York Southern·Petition date May 20, 2019

Research this case Track this case Sign in

OverviewProfessionals

Key professionals

Financial Advisor

KPMG LLP

Financial Advisor

Province, LLC

Investment Banker

Moelis & Company

Chief Restructuring Officer

AP Services, LLC

Judge: Martin Glenn
Petition assets: $100M–$500M
Petition liabilities: $100M–$500M
Industry: Healthcare
Debtors: 2

Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing and commercializing treatments for rare diseases. An indirect wholly-owned subsidiary of Novelion Therapeutics Inc., the company operates in the United States, Canada, Europe, Latin America, and Japan. Its portfolio includes JUXTAPID, used to treat homozygous familial hypercholesterolemia, and MYALEPT, a treatment for lipodystrophy complications. In 2018, the company generated $130.4 million in net revenue.

Case background, summaries, and key terms are generated from the filings on this docket. Docket entries and documents come from the court.

Report a data error